Research Topics
| W W LeitnerSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
DNA and RNA-based vaccines: principles, progress and prospectsW W Leitner
National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892 1502, USA
Vaccine 18:765-77. 1999..Thus, the enhanced immunogenicity of 'self-replicating' genetic vaccines may be a result of the production of pro-inflammatory dsRNA, which mimics an RNA-virus infection of host cells...- Type I Interferons are essential for the efficacy of replicase-based DNA vaccinesWolfgang W Leitner
Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Vaccine 24:5110-8. 2006..These results suggest a central role for Type I IFNs in the mechanism of replicase-based DNA vaccines and indicate that vaccines can be enhanced by enabling their capacity to triggering innate anti-viral defense pathways... - Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccinesWolfgang W Leitner
Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42 Bethesda, MD 20892 1502, USA
Vaccine 22:1537-44. 2004..Our findings also provide an explanation for the paradoxical observation that replicase-based DNA vaccines are much more immunogenic than conventional constructs despite reduced antigen production... - Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacyWolfgang W Leitner
Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Malar J 9:145. 2010..Finding shortcomings of both approaches, an alternative approach was explored, i.e., the subcutaneous challenge... - Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathwaysWolfgang W Leitner
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Nat Med 9:33-9. 2003.... - Enhancement of tumor-specific immune response with plasmid DNA replicon vectorsW W Leitner
National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
Cancer Res 60:51-5. 2000..Because of their safety and efficacy, plasmid DNA replicons may be useful in the development of recombinant vaccines for infectious diseases and cancer... 
Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvantsW W Leitner
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Curr Pharm Des 7:1641-67. 2001..Despite highly promising results in many animal tumor models the efficacy of nucleic acid vaccines and adjuvants in the clinic remains to be seen...- Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigenC E Touloukian
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892
Cancer Res 61:8100-4. 2001..polypeptide-specific CD8+ T cells capable of recognizing P.polypeptide expressing human tumor cell lines in an HLA-A*0201-restricted fashion. Thus, P.polypeptide may be valuable in the creation of novel therapeutic anticancer vaccines... - The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosisS Frank
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Behesda, Maryland 20892, USA
Dev Cell 1:515-25. 2001..Remarkably, inhibition of Drp1 blocks cell death, implicating mitochondrial fission as an important step in apoptosis... - Assumptions of the tumor 'escape' hypothesisNicholas P Restifo
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Semin Cancer Biol 12:81-6. 2002..The dysregulation characteristic of the transformed genome is also what makes tumor immunity, a specialized form of autoimmunity, possible... - Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell functionChristopher E Touloukian
National Cancer Institute, NIH, Building 10, Room 2B42, Bethesda, MD 20892, USA
Cancer Res 62:5144-7. 2002..These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes... - Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1Christopher E Touloukian
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 170:1579-85. 2003..Thus, the tumor-bearing state reverses, in part, the tolerance of T cells that results from the normal expression of tissue differentiation Ags... - Replicase-based DNA vaccines for allergy treatmentSandra Scheiblhofer
Department of Molecular Biology, University of Salzburg, Salzburg, Austria
Methods Mol Med 127:221-35. 2006.... - Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitizationMaximilian Gabler
Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg, Austria
J Allergy Clin Immunol 118:734-41. 2006..CLINICAL IMPLICATIONS: Their high safety profile makes replicon-based DNA vaccines promising candidates for treatment of type I allergies in the clinic... - Inhibitory effects of B cells on antitumor immunitySatoshi Inoue
Center for Biologics Evaluation and Research, Division of Hematology, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
Cancer Res 66:7741-7. 2006..Our studies provide the first mechanistic basis for the concept that B-cell depletion could therapeutically enhance antitumor immune responses to certain tumors by decreasing IL-10 production from B cells... - Complement 3d: from molecular adjuvant to target of immune escape mechanismsElke S Bergmann-Leitner
Department of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Room 3W76, Silver Spring, MD 20910, USA
Clin Immunol 121:177-85. 2006.... - Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh
Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences AFRIMS, Bangkok, Thailand
Vaccine 24:4167-78. 2006..In field studies, RTS,S/AS02A reduced malaria infection, clinical episodes, and disease severity. Heterologous prime-boost immunization regimens, optimally spaced, might improve the protective immunity of RTS,S/AS02A... - Is genetic vaccination against allergy possible?Richard Weiss
Department of Molecular Biology, Division of Allergy and Immunology, University of Salzburg, Salzburg, Austria
Int Arch Allergy Immunol 139:332-45. 2006.... - Genetic immunization with LYVE-1 cDNA yields function-blocking antibodies against native proteinAdela R Cardones
Dermatology, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 12N258, Bethesda, MD 20892, USA
Microvasc Res 71:32-9. 2006..In summary, gene gun-assisted delivery of cDNA encoding LYVE-1 into skin resulted in reliable production of antisera that specifically and functionally recognized native LYVE-1 protein... - Design of protective and therapeutic DNA vaccines for the treatment of allergic diseasesRichard Weiss
Department of Molecular Biology, University of Salzburg, A-5020 Salzburg, Austria
Curr Drug Targets Inflamm Allergy 4:585-97. 2005..Finally, the development of DNA multi vaccines and fusion vaccines for protective and therapeutic applications against certain groups of allergens is addressed... - Danger, death and DNA vaccinesElke S Bergmann-Leitner
Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Microbes Infect 6:319-27. 2004..Among the countless approaches to improve them is the stimulation of the innate immune system by promoting the apoptotic death of the transfected host cells, which is the focus of this review... - DNA vaccines and apoptosis: to kill or not to kill?Wolfgang W Leitner
National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Clin Invest 112:22-4. 2003 - DNA vaccines for non-infectious diseases: new treatments for tumour and allergyWolfgang W Leitner
Immunology Group, Institute of Chemistry and Biochemistry, University of Salzburg, Salzburg, Austria
Expert Opin Biol Ther 3:627-38. 2003..These strategies, individually or in combination, hold the potential of making DNA vaccines useful for application in the clinic... - Myth, menace or medical blessing? The clinical potential and problems of genetic vaccinesWolfgang W Leitner
Expert Opin Biol Ther 3:1-4. 2003 - Identification and targeting of tumor escape mechanisms: a new hope for cancer therapy?Elke S Bergmann-Leitner
Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Curr Pharm Des 9:2009-23. 2003..Any tumor therapy puts selective pressure on tumors thus favoring the outgrowth of therapy-resistant variants. This review summarizes current knowledge on tumor escape mechanisms and some of the efforts to overcome these mechanisms...